1. Home
  2. BEEP vs CHRS Comparison

BEEP vs CHRS Comparison

Compare BEEP & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mobile Infrastructure Corporation

BEEP

Mobile Infrastructure Corporation

N/A

Current Price

$2.62

Market Cap

106.1M

Sector

Finance

ML Signal

N/A

Logo Coherus BioSciences Inc.

CHRS

Coherus BioSciences Inc.

N/A

Current Price

$1.16

Market Cap

177.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BEEP
CHRS
Founded
2015
2010
Country
United States
United States
Employees
18
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
106.1M
177.7M
IPO Year
2021
2014

Fundamental Metrics

Financial Performance
Metric
BEEP
CHRS
Price
$2.62
$1.16
Analyst Decision
Buy
Buy
Analyst Count
3
6
Target Price
$5.83
★ $7.75
AVG Volume (30 Days)
17.2K
★ 1.1M
Earning Date
11-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 472.00
EPS
★ N/A
N/A
Revenue
★ $35,075,000.00
N/A
Revenue This Year
$1.47
$44.19
Revenue Next Year
$11.40
$65.06
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$1.29
$1.09
52 Week High
$3.78
$2.62

Technical Indicators

Market Signals
Indicator
BEEP
CHRS
Relative Strength Index (RSI) 48.76 43.48
Support Level $2.73 N/A
Resistance Level $2.94 $1.53
Average True Range (ATR) 0.09 0.09
MACD -0.03 -0.01
Stochastic Oscillator 33.33 30.30

Price Performance

Historical Comparison
BEEP
CHRS

About BEEP Mobile Infrastructure Corporation

Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Share on Social Networks: